The Psychiatrist (1997) 21: 680-683. doi: 10.1192/pb.21.11.680
© 1997 The Royal College of Psychiatrists
This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Taylor, D.
Right arrow Articles by Paton, C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Taylor, D.
Right arrow Articles by Paton, C.

Evaluating and improving the quality of risperidone prescribing

David Taylor, Chief Pharmacist*

Bethlem and Maudsley NHS Trust, London SE5 8AZ

Robert Holmes, Principal Pharmacist

Royal London Hospital (Mile End), Bancroft Road, London E1 4DG

Trudi Hilton, Principal Pharmacist

Ealing Hospital, Uxbridge Road, Middlesex UB1 3HW

Carol Paton, Chief Pharmacist

Bexley Hospital, Old Bexley Lane, Bexley DA5 2BW

* Correspondence

Clinical studies suggest that risperidone is an effective antipsychotic with a low incidence of extrapyramidal adverse effects. In a prescription survey of several trusts, we found that risperidone was widely prescribed at high doses alongside typical neuroleptics and anticholinergic drugs. We also demonstrated that prescribing in a single trust can be improved by simple interventions. Risperidone should be prescribed as the sole antipsychotic at doses below 8 mg/day to realise fully its clinical advantages. Few prescriptions met this standard.




This article has been cited by other articles:


Home page
 The PsychiatristHome page
D. Taylor
Antipsychotic polypharmacy - confusion reigns
The Psychiatrist, February 1, 2010; 34(2): 41 - 43.
[Abstract] [Full Text] [PDF]

Home page
 The PsychiatristHome page
D. Taylor
Antipsychotic prescribing -- time to review practice
The Psychiatrist, November 1, 2002; 26(11): 401 - 402.
[Full Text] [PDF]

Home page
 The PsychiatristHome page
D. Taylor, S. Mir, and R. Kerwin
Prescribing in schizophrenia. Evaluating the effect of introducing a new treatment protocol
The Psychiatrist, March 1, 2000; 24(3): 106 - 108.
[Abstract] [Full Text]